Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06937099 · ClinicalTrials.gov registry record · Phase 3
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
A Phase 3 study of Crohn's Disease and Obesity or Overweight, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 290
- Enrollment target
- 20
- Study locations
NCT06937099 is a Phase 3 study of Crohn's Disease and Obesity or Overweight that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 290 participants, below the 2,412-participant average among 104 other Crohn's Disease trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT06937099, a Phase 3 study of Crohn's Disease and Obesity or Overweight, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 290 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight. The maximum duration of this study is up to 61 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tirzepatide
- DRUG Mirikizumab
Study Locations (20)
Florida
- Research Associates of South Florida - Miami - Southwest 8th Street - Miami
- Gastro Health Research - Miami - Miami
- Orlando Health - Orlando
- Digestive and Liver Center of Florida - Orlando
- Gastro Health Research - Pensacola - Pensacola
- Precision Clinical Research - Sunrise
California
- Smart Cures Clinical Research - Anaheim
- Cedars-Sinai Medical Center - Beverly Hills
- United Medical Doctors - Los Alamitos - Los Alamitos
- California Medical Research Associates - Northridge
Indiana
- Indiana University Health University Hospital - Indianapolis
- Gastroenterology Health Partners - New Albany
Louisiana
- Care Access - New Iberia - New Iberia
- Louisiana Research Center - Shreveport
Alabama
- Digestive Health Specialists - Dothan
Idaho
- Grand Teton Research Group - Idaho Falls
Illinois
- Rush University Medical Center - Chicago
Kentucky
- Gastroenterology Health Partners - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290 participants |
| Start Date | 2025-06-26 |
| Est. Completion | 2028-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06937099
The ClinicalTrials.gov registry entry for NCT06937099 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 290 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,412-participant average among 104 other Crohn's Disease trials with a reported enrollment target (88% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Crohn's Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06937099 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, Indiana.
Frequently Asked Questions
What is clinical trial NCT06937099 about?
NCT06937099 is a clinical study titled "Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight". The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight. The maximum duration of this study is up to 6...
What is the current status of trial NCT06937099?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 290 participants. The study started on 2025-06-26. Estimated completion is 2028-05.
What conditions does trial NCT06937099 study?
This clinical trial studies the following conditions: Crohn's Disease, Obesity or Overweight.
What interventions are being tested in trial NCT06937099?
The interventions under investigation include: Placebo (DRUG), Tirzepatide (DRUG), Mirikizumab (DRUG).
Who is sponsoring clinical trial NCT06937099?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06937099 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
RECRUITING · Phase 3
-
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
RECRUITING · Phase 3
-
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
RECRUITING · Phase 3
-
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 3
-
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
RECRUITING · Phase 3
-
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.